ADAG תחזית צמיחת רווח נקי למניה לשנה הבאה Adagene Inc

Adagene leverages the Chinese immuno-oncology network SAFEbody and partnerships with global behemoths. The shift in the consensus net profit growth estimate visualizes these expectations, where -40.00 captures a new level. Business efficiency is driven by robotic antibody expression lines and AI-driven design of "smart" drugs that precisely target tumors while eliminating unnecessary side effects.

This indicator reflects the analysts' consensus forecast for earnings per share changes, allowing for an assessment of the business's fundamental growth potential. The expected annual EPS growth rate for the coming year aggregates market expectations, where extreme values signal a risk of correction. For Adagene (ADAG), this trend depends on the efficiency of AI antibody design and the success of clinical trials involving physicians.